196 related articles for article (PubMed ID: 3100634)
1. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages.
Bara S; Lint TF
J Immunol; 1987 Feb; 138(4):1303-9. PubMed ID: 3100634
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of lymphokine-activated macrophages in host defense against neoplasia.
Fernandez-Cruz E; Ulich T; Schreiber RD
J Immunol; 1985 May; 134(5):3489-96. PubMed ID: 3920323
[TBL] [Abstract][Full Text] [Related]
3. [Experimental analysis of cytotoxicity mediated by activated macrophages against glioma cells in mice].
Ohyama K
Nihon Geka Hokan; 1993 Mar; 62(2):92-115. PubMed ID: 8239865
[TBL] [Abstract][Full Text] [Related]
4. Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: lysis of tumor cells and macrophages by C. parvum-induced killer cells.
Chen MF; Suzuki H; Yano S
Anticancer Res; 1992; 12(2):451-6. PubMed ID: 1580562
[TBL] [Abstract][Full Text] [Related]
5. [Effects of interferon-gamma on cytotoxicity of murine activated macrophages against murine glioma cells].
Ohyama K; Kikuchi H; Oda Y; Moritake K; Yamasaki T
No To Shinkei; 1993 Jun; 45(6):525-30. PubMed ID: 8363848
[TBL] [Abstract][Full Text] [Related]
6. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
[TBL] [Abstract][Full Text] [Related]
7. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
Mosser DM; Edelson PJ
J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
[TBL] [Abstract][Full Text] [Related]
8. Activation of murine macrophages. I. Different pattern of activation by poly I:C than by lymphokine or LPS.
Taramelli D; Varesio L
J Immunol; 1981 Jul; 127(1):58-63. PubMed ID: 6787132
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of a deficiency of AKR mouse macrophages for their response to lipid A activation for tumor cytotoxicity by complement subcomponent C1q: role of IFN-gamma.
Leu RW; Zhou AQ; Rummage J; Fast DJ; Shannon BJ
J Immunol; 1991 Aug; 147(4):1315-21. PubMed ID: 1907994
[TBL] [Abstract][Full Text] [Related]
10. Exogenous C1q reconstitutes a secondary deficiency of C5-deficient AKR mouse macrophages for FcR-dependent cellular cytotoxicity and phagocytosis.
Leu RW; Zhou AQ; Kennedy MJ; Shannon BJ
J Immunol; 1991 Feb; 146(4):1233-9. PubMed ID: 1991965
[TBL] [Abstract][Full Text] [Related]
11. High strength binding of P815 mastocytoma cells is not necessary for their lysis by macrophages which have been primed and triggered in vitro.
Lu CY; Lombardi MJ; Shea CM; Dustin LB
J Immunol; 1988 Aug; 141(4):1083-90. PubMed ID: 3135320
[TBL] [Abstract][Full Text] [Related]
12. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
13. Quantitative studies of the secretion of complement component C3 by resident, elicited and activated macrophages. Comparison with C2, C4 and lysosomal enzyme release.
Zimmer B; Hartung HP; Scharfenberger G; Bitter-Suermann D; Hadding U
Eur J Immunol; 1982 May; 12(5):426-30. PubMed ID: 7094993
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of tumor targets to liver macrophage-mediated cytotoxicity.
Gardner CR; Wasserman AJ; Laskin DL
Cancer Res; 1987 Dec; 47(24 Pt 1):6686-91. PubMed ID: 3119198
[TBL] [Abstract][Full Text] [Related]
15. Activation of complement on the surface of cells infected by human immunodeficiency virus.
Spear GT; Landay AL; Sullivan BL; Dittel B; Lint TF
J Immunol; 1990 Feb; 144(4):1490-6. PubMed ID: 1968081
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
17. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.
Weinhold KJ; Bolognesi DP; Matthews TJ
J Natl Cancer Inst; 1985 Oct; 75(4):717-24. PubMed ID: 3862904
[TBL] [Abstract][Full Text] [Related]
18. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
19. Suppression of cell-mediated tumor cell lysis and complement-induced cytotoxicity by trypan blue.
Scornik JC; Ruiz P; Hoffman EM
J Immunol; 1979 Sep; 123(3):1278-84. PubMed ID: 469250
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
